MIZKO Trademark

Trademark Overview


On Thursday, August 15, 2019, a trademark application was filed for MIZKO with the United States Patent and Trademark Office. The USPTO has given the MIZKO trademark a serial number of 88580148. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, February 13, 2023. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The MIZKO trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Pharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Fertility enhancing preparations; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical ...

Contraceptive device, namely, an intrauterine device
mizko

General Information


Serial Number88580148
Word MarkMIZKO
Filing DateThursday, August 15, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, February 13, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 12, 2019

Trademark Statements


Goods and ServicesPharmaceuticals and medicines affecting the central nervous system; Pharmaceuticals and medicines affecting the circulatory systems; Pharmaceuticals and medicines affecting the sensory organs; Pharmaceuticals and medicines affecting the urogenital organs; Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Fertility enhancing preparations; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Contraceptive preparations
Goods and ServicesContraceptive device, namely, an intrauterine device

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, August 30, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateFriday, August 30, 2019
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Trademark Events


Event DateEvent Description
Monday, February 13, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, February 13, 2023ABANDONMENT - NO USE STATEMENT FILED
Thursday, February 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, February 2, 2023TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, February 2, 2023ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, February 2, 2023TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, August 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 1, 2022SOU EXTENSION 5 GRANTED
Thursday, July 7, 2022SOU EXTENSION 5 FILED
Tuesday, July 26, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, July 7, 2022TEAS EXTENSION RECEIVED
Thursday, July 7, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, July 7, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, July 7, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 5, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 3, 2022SOU EXTENSION 4 GRANTED
Monday, January 3, 2022SOU EXTENSION 4 FILED
Monday, January 3, 2022TEAS EXTENSION RECEIVED
Friday, July 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, July 7, 2021SOU EXTENSION 3 GRANTED
Wednesday, July 7, 2021SOU EXTENSION 3 FILED
Wednesday, July 7, 2021TEAS EXTENSION RECEIVED
Friday, December 11, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 9, 2020SOU EXTENSION 2 GRANTED
Wednesday, December 9, 2020SOU EXTENSION 2 FILED
Wednesday, December 9, 2020TEAS EXTENSION RECEIVED
Saturday, July 4, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 2, 2020SOU EXTENSION 1 GRANTED
Thursday, July 2, 2020SOU EXTENSION 1 FILED
Thursday, July 2, 2020TEAS EXTENSION RECEIVED
Tuesday, January 7, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 12, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 12, 2019PUBLISHED FOR OPPOSITION
Wednesday, October 23, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, October 4, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 3, 2019ASSIGNED TO EXAMINER
Friday, August 30, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, August 19, 2019NEW APPLICATION ENTERED